Aspen Pharmacare Holdings Limited · JSE:APN

Aspen Pharmacare — FY2015 Earnings Presentation

68 slides from Aspen Pharmacare's earnings presentation, Sep 11, 2015

  1. Slide 1: Annual Results Presentation

    Annual Results Presentation For the year ended 30 June 2015

  2. Slide 2: Highlights

    Highlights +22% +14% +15% Revenue Operating profit Normalised headline EPS FY 2015 36.1 FY 2015 8.4 FY 2015 1 219 FY 2014 29.5 FY 2014 7.4 FY 2014 1 064 R'billion R'billion Cents +26% +1% +15% Cash generated from Net borrowings Distribution to operating activities shareholders FY 2015 4.8 FY 2015 30

  3. Slide 3: Record of unbroken growth

    Record of unbroken growth (Normalised) headline earnings per share since listing 1219 1064 837 Cents 660 555 487 389 210 231 185 138 79 104 47 63 20 34 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 3

  4. Slide 4: Abridged Group statement of comprehensive income

    Abridged Group statement of comprehensive income R’million FY 2015 FY 2014 Change Net revenue 36 127 29 515 22% Cost of sales (18 873) (15 793) Gross profit 17 254 13 722 26% Net operating expenses (8 317) (5 907) EBITA 8 937 7 815 14% Amortisation (487) (390) Operating profit 8 450 7 425 14% Net fu

  5. Slide 5: Gross revenue bridge

    Gross revenue bridge 40 000 1 156 24 38 046 5 843 410 35 000 31 433 30 000 25 000 R'million 20 000 15 000 10 000 5 000 0 FY 2014 International Asia Pacific South Africa Sub-Saharan FY 2015 Africa 5

  6. Slide 6: Gross revenue by customer geography

    Gross revenue by customer geography 12 000 +45% 10 000 +16% -3% 8 000 R'million 6 000 +44% +1% +143% 4 000 -10% 2 000 - South Africa Sub-Saharan Asia Pacific Europe CIS Latin America Hyperinflationary Rest of the Africa economy World FY 2014 FY 2015 6

  7. Slide 7: Operating margins

    Operating margins Normalised EBITA margin % International South Africa Asia Pacific Sub-Saharan Africa Group 0.0% 5.0% 10.0% 15.0% 20.0% 25.0% 30.0% 35.0% FY 2014 FY 2015 7

  8. Slide 8: Net funding costs

    Net funding costs R’million FY 2015 FY 2014 Net interest paid (1 450) (1 018) Debt raising fees on acquisitions (142) (155) Net foreign exchange (loss)/gain (479) 81 Foreign exchange gain on settlement of transaction funding liability - 249 Fair value losses on financial instruments (1) (86) Notiona

  9. Slide 9: Reconciliation of earnings per share

    Reconciliation of earnings per share For the year ended 30 June Cents FY 2015 FY 2014 Change Basic earnings per share (EPS) 1 139.8 1 097.9 4% Net impairments 37.2 23.6 Net profit on sale of assets (27.1) (105.2) Headline EPS (HEPS) 1 149.9 1 016.3 13% Restructuring costs 21.6 6.5 Capital raising fe

  10. Slide 10: Revenue analysis of major currencies

    Revenue analysis of major currencies Rate Avg rate for Avg rate for Revenue benefit/ year to June year to June Variance year to June (loss) in 2014 2015 2015 R'm R'm Rand/ EUR 14.20 13.61 4% 8 472 (367) Rand/AUD 9.55 9.48 1% 6 684 (55) Rand/USD 10.44 11.47 -9% 3 269 295 Rand/VEF 1.25 1.93 -35% 2 383

  11. Slide 11: Key currency movements vs USD – Jul 2014 to Jun 2015

    Key currency movements vs USD – Jul 2014 to Jun 2015 1.20 1.10 1.00 0.90 0.80 0.70 0.60 0.50 0.40 EUR AUD MXN BRL RUB ZAR 11

  12. Slide 12: Working capital and cash generation

    Working capital and cash generation R’million FY 2015 FY 2014 Net working capital 14 327 13 018 Net working capital excluding Oss 10 591 9 842 Working capital as % of revenue 40% 37% Less: Attributable to Oss -8% -5% Working capital excluding Oss as % of revenue 32% 32% Cash generation FY 2015 FY 20

  13. Slide 13: PPE capital expenditure

    PPE capital expenditure 1 800 1 593 1 600 1 400 1 329 1 200 R'million 1 000 800 632 652 667 552 600 470 434 400 295 215 253 168 200 - FY 2010 FY 2011 FY 2012 FY 2013 FY 2014 FY 2015 Capital Expenditure Depreciation 13

  14. Slide 14: Borrowings

    Borrowings Year ended 30 June R’million FY 2015 FY 2014 Net borrowings of R30.0 billion Opening balance 29 765 11 058 Cash flow from operating activities (4 839) (3 836) International 50.9% Capital expenditure 2 417 2 029 South Africa Proceeds from sale of assets (3 648) (1 005) 32.5% Acquisitions o

  15. Slide 15: Borrowings

    Borrowings Blended interest rates for borrowings as at 30 June 2015 Analysis of R30.0 billion net Weighted borrowings Debt denomination average rate p.a. Net borrowings 30.0 ZAR 7.00% USD 2.75% Cash 8.7 AUD 4.60% Current 13.2 Key indicators FY 2015 FY 2014 Interest cover ratio 6.2x 7.8x Non-current

  16. Slide 16: Exposure to Venezuela

    Exposure to Venezuela  Restricted currency flows  Wide range of applicable currency translation – from VEF6.30 = 1USD to VEF600 = 1USD  Aspen has translated Bolivars at VEF6.30 = 1USD – the official rate for medicines and infant nutritional products  During the year to 30 June 2015 Aspen receive

  17. Slide 17: Group overview

    Group Group overview Revenue by customer geography* R’million FY 2015 FY 2014 % change International 18 157 12 430 46% South Africa 8 608 7 451 16% Asia Pacific 8 504 8 799 -3% Sub-Saharan Africa 2 777 2 753 1% Total 38 046 31 433 21% * Classification by customer geography is based on the destinatio

  18. Slide 18: International revenue analysis

    International Revenue analysis Revenue by customer geography R’million FY 2015 FY 2014 % change Europe CIS 10 456 7 200 45% Commercial sales 6 902 3 958 74% FDF and API sales 3 555 3 243 10% Latin America 6 128 3 485 76% North America 894 1 081 -17% - Commercial sales 599 737 -19% - API sales 295 34

  19. Slide 19: International: Europe CIS

    International Europe CIS Revenue by customer geography R’million FY 2015 FY 2014 % change Commercial sales 6 902 3 958 74% - Anticoagulants 4 558 2 310 97% - Other brands 2 344 1 648 42% API sales 3 027 2 729 11% Finished form sales 528 513 3% Total 10 456 7 200 45%  Europe CIS +6% (H2:H1)  Antico

  20. Slide 20: Europe CIS – Transformation into an independent operating region

    International Europe CIS – Transformation into an independent operating region Commercial revenue in R'million 8 000 Acquisition of MSD Acquisition of product portfolio, Mono 6 902 7 000 Arixtra and Fraxiparine Embolex 6 000 5 000 3 958 4 000 3 000 2 000 959 1 000 - FY2013 FY2014 FY2015  Sales oper

  21. Slide 21: Europe CIS – LWMH market value as at December 2014

    International Europe CIS – LWMH market value as at 31 December 2014 Europe CIS market USD3.3 billion Pfizer Other 10% 4% Leo 10% Sanofi 58% Aspen* 18% Source: IMS December 2014 * Includes Seleparina – owned by Aspen licensed to Italfarmaco  LWMH growth in volume (+1%) and value (+3%) ◦ Hospital sal

  22. Slide 22: Russia – June 2015 hospital injectables anti-thrombosis market

    International Russia – June 2015 hospital injectables anti-thrombosis market Source: IMS Health MAAS, June 2015  Aspen has now overtaken Sanofi 22

  23. Slide 23: Aspen's anticoagulant portfolio presentation across Europe CIS

    International Aspen’s anticoagulant portfolio presentation across Europe CIS  Only global offering of such a broad range of specialist injectable anticoagulants  Providers have advantage of a single supplier that addresses broad clinical needs ◦ Bodyweight independent application ◦ Local sensitive

  24. Slide 24: Europe CIS – Broad basket offers opportunity for targeted positioning

    International Europe CIS – Broad basket offers opportunity for targeted positioning  Strategic focus on oncology with Fraxiparine ◦ Longer usage periods for safety reasons ◦ Existing onco portfolio growing  Fraxodi – the only once daily LMWH product for deep vein thrombosis  Focused promotional s

  25. Slide 25: Europe CIS – Commercial strategy and highlights

    International Europe CIS – Commercial strategy and highlights  Therapeutic area performing ◦ In spite of introduction of orals  Barriers to entry high ◦ API – biochemical ◦ FDF – sterile pre-filled syringes ◦ Commercial − Need volumes − Price already very low  Significant reduction in cost of goo

  26. Slide 26: Europe CIS – API and FDF manufacture

    International Europe CIS – API and FDF manufacture  Sales increase of 11% ◦ Euro increase of 16% ◦ API sales in 2014 included GSK sales Objective is to drive increasing sales values/volumes off a decreasing cost base API manufacture  Sourcing for heparin volumes ◦ Mucosa sourcing expanded and cost

  27. Slide 27: International: Latin America

    International Latin America Revenue by customer geography R’million FY 2015 FY 2014 % change Brazil 792 788 1% Spanish Latin America 5 336 2 697 98% - Nutritional sales 3 078 1 519 103% Venezuela 1 759 683 158% Rest of Spanish LatAm 1 319 836 58% - Pharmaceutical sales 2 258 1 178 92% Venezuela 945

  28. Slide 28: International: Venezuela

    International Venezuela  Economy unstable and vulnerable ◦ 97% dependency on oil exports  Has fixed exchange rate regime  Application for creditor payments made through a central authority ◦ Payment erratic and for many non existent ◦ For now Aspen has enjoyed improved payments − assistance from

  29. Slide 29: Spanish Latin America – Strategic focus in 2015

    International Spanish Latin America – Strategic focus in 2015  Retail to Detail strategy - implemented regionally  Nutritionals margin improvement ◦ More to follow Mexico Caricam Costa Rica  Anticoagulants injectable responding Panama Venezuela ◦ +70% Mexico Colombia ◦ +35% Andean markets Ecuador

  30. Slide 30: Nutritionals performance

    International Nutritionals performance Aspen Infant Milk Formulas – LatAm sales in MAT USD excluding Venezuela Jun-13 Mar-14 Jul-13 Jan-14 Feb-14 Jun-14 Jul-14 Jan-15 Feb-15 Mar-15 May-13 Aug-13 Sep-13 Oct-13 Nov-13 Dec-13 Apr-14 May-14 Aug-14 Sep-14 Oct-14 Nov-14 Dec-14 Apr-15 MAT in USDm Source: I

  31. Slide 31: Spanish Latin America – Performance of pharma products

    International Spanish Latin America – Performance of pharma products Spanish LatAm 2015 –transaction overview 25% 18.7% MSD PRODUCT 20% PORTFOLIO 13.0% 15% 9.7% INITIAL GSK 9.2% TRANSACTION Growth in % 10% GSK ONCOLOGY 5% 0% GSK -8.7% ANTICOAGULANTS -5% NOVARTIS -10% TOFRANOL & ENABLEX -15% Source:

  32. Slide 32: South Africa revenue analysis

    South Africa Revenue analysis Revenue by customer geography R’million FY 2015 FY 2014 % change Pharmaceutical Private sector 4 857 4 346 12% Public sector 1 573 1 384 14% - ARV tender 969 801 21% - Other tenders 604 583 4% Consumer 1 369 1 116 23% FDF and API manufacturing sales 809 605 34% Total 8

  33. Slide 33: South Africa private pharmaceutical market

    South Africa Private pharmaceutical market  Total private market valued at R33.1 billion (+8.2%) ASPEN MAT VALUE MKT MAT SHARE GROWTH GROWTH ASPEN 16.1% 9.5% 8.2% ETHICAL 9.6% 10.0% 5.4% GENERIC 29.6% 11.5% 10.5% OTC 11.5% 6.8% 9.9% Source: IMS June 2015  Leading pharmaceutical company with 16.1%

  34. Slide 34: South Africa private market pharma

    South Africa Private market pharma  ARV market share increasing in competitive segment MAT value share trend 45% ASPEN 40% CIPLA 35% 30% MYLAN MERCK & CO  Foxair sales performance continues 25% 20% NOVAGEN PHARMA ABBVIE ◦ Discounted access/volume growth ◦ Sales greater than Seretide historics ADCO

  35. Slide 35: Infant milk formula

    South Africa Infant milk formula  Aggressive market share gain in 2015 ◦ Market share all-time high in both volume (26.3%) and value (23.3%) ◦ S-26 stock situation improving − Returning to growth ◦ Infacare classic − Driving category volume growth 10.4% (Cat 3.5%) ASPEN NUTRITIONALS: VOLUME SHARE 2

  36. Slide 36: SA strategy

    South Africa SA strategy  Strategic review of portfolio ◦ Decision taken to drive focus − Manage portfolio within increasing compliance requirements − Resource commitment against return − Portfolio review of Aspen’s aspirations therapeutically  A broad portfolio consisting largely of imported ster

  37. Slide 37: SA summary

    South Africa SA summary  Aspen private market business continues to perform ◦ As it has done consistently for the past 17 years ◦ Rock solid defensively with aggressive growth trajectory  IMFs had a turbulent start ◦ Stock outs ◦ Market share loss exacerbated by delay in Competition Commission ◦ A

  38. Slide 38: Asia Pacific

    Asia Pacific Asia Pacific Revenue by customer geography R’million FY 2015 FY 2014 % change Australia and New Zealand 7 217 7 876 -8% Asia 1 287 923 39% Total 8 504 8 799 -3%  Australian sales impacted ◦ By both divestments and license terminations − Particularly in H2 − Principle driver termination

  39. Slide 39: Australia and New Zealand

    Asia Pacific Australia and New Zealand Revenue by customer geography R’million FY 2015 FY 2014 % change Owned pharma brands - continuing 3 429 3 369 2% Nutritionals 975 904 8% Total owned brand sales 4 404 4 273 3% Licensed products 1 217 1 516 -20% Contract manufacturing 204 342 -40% Total other sa

  40. Slide 40: Australia – Pharmaceutical sector

    Asia Pacific Australia – Pharmaceutical sector  As at 30 June 2015 Leading manufacturers by scripts written by GPs ◦ Market growth of +3.1% to AUD14.6 billion in value ◦ Driven by volume growth +6.9% primarily generics Aspen ◦ Price decreases Others 24% 18% − Net generic pricing would deflate this

  41. Slide 41: Australia – Strategic brand imperatives

    Asia Pacific Australia – Strategic brand imperatives  Aspen has a strong supply chain Lamictal ◦ Good understanding of generic market 215 000 +4.8% MAT Units  To ensure sustainability 210 000 ◦ Focus on volume retentions & growth 205 000  Initial phase 200 000 ◦ Increased generic competition 195

  42. Slide 42: Nutritionals continue to perform

    Asia Pacific Nutritionals continue to perform  Good revenue growth from base S-26 Gross sales by channel (AUDm) ◦ Innovation - Junior & Comfort variants − Launched in April 2013 continue to grow ◦ Diversification of retail channels paying off − Strong brand support in pharmacies − Additional listin

  43. Slide 43: Aspen Australia summary overview and strategy

    Asia Pacific Aspen Australia summary overview and strategy  Business was a start up in 2001 ◦ Built on acquisitive & organic growth including licensing ◦ Innovative, professional commercial strategies employed  Owned brands ◦ Aspen base brands ◦ Acquired Sigma brands ◦ Infant milk formulas  Licen

  44. Slide 44: Aspen Australia summary overview and strategy

    Asia Pacific Aspen Australia summary overview and strategy  Since acquiring Sigma ◦ Integrating businesses − Both regionally and therapeutically ◦ Consolidating manufacture and optimising the supply chain ◦ Driving generic business growth & profitability ◦ Consolidating OTC and prescription franchi

  45. Slide 45: Assessment of objectives achieved

    Asia Pacific Assessment of objectives achieved  Only 1 local manufacturing site ◦ Remaining sites closed & divested  Over 2 100 SKUs ◦ Reduced to less than 600 ◦ Retained 80% of profitability  Focus on managing own brands ◦ Resource not distracted ◦ IMF growth business ◦ Higher margin base busine

  46. Slide 46: Asian revenue reached R1.29 billion

    Asia Pacific Asian revenue reached R1.29 billion Rest of Asia China 12% 3% Hong Kong 5% Japan 37% Indonesia 7% Taiwan 7% Malaysia 10% Philippines 19%  Revenue growth of 39% and greater than R1 billion ◦ Driven both organically and acquisitively  Philippines – 10% growth as licensed products discon

  47. Slide 47: Sub-Saharan Africa revenue analysis

    Sub-Saharan Africa Revenue analysis Regional revenue growth rates Gross sales R2 777m (2014: R2 752m) West Africa -2% East Africa 35% West Africa 54% East Africa 0% Southern Africa Southern Africa +18% 11%  Revenue growth of 1%  Normalised EBITA growth of -6% 47

  48. Slide 48: Sub-Saharan Africa performance

    Sub-Saharan Africa Performance  Collaboration sales flat year-on-year  Performance negatively impacted by: ◦ Supply challenges for key products − Sales impact > R135 million ◦ Significant currency devaluation in key markets ◦ Political unrest and elections in Nigeria which is the most significant

  49. Slide 49: Unpacking operational & strategic synergies

    Group Unpacking operational & strategic synergies  Bedded down 3 large/complex transaction groups ◦ GSK – facility & biological products ◦ Merck – facilities including biochem facilities & niche products ◦ Nestlé – IMF across Latin America, South Africa, Australia and facility  We have achieved ◦

  50. Slide 50: Unpacking operational & strategic synergies: key areas

    Unpacking operational & strategic synergies The really big 5 operational synergies  Five key areas for material synergies have been identified these include Synergies at: Oss NDB Mono Embolex Infant milk formulas Port Elizabeth 50

  51. Slide 51: Oss and NDB - Cost reduction and capacity initiatives

    Unpacking operational & strategic synergies Oss and NDB - Cost reduction and capacity initiatives  Improvement in technologies/machinery ◦ High speed line in NDB − Addresses quality and output ◦ Moleneid’s unsustainable plants decommissioned/repurposed − Sustainability, EHS and competitiveness − In

  52. Slide 52: Oss / NDB and Mono Embolex – Commercial initiatives

    Unpacking operational & strategic synergies Oss / NDB and Mono Embolex – Commercial initiatives  Increased capacity utilisation ◦ Third party growth at NDB − Attempt to increase volumes by at least 50% • Vaccines manufacturers interested − Transfer manufacture from slower lines to new line ◦ API sa

  53. Slide 53: Quantifying the synergies

    Unpacking operational & strategic synergies Quantifying the synergies  IMF ◦ Reduction in COGS − Global procurement − Commodity decreases − Operational expenses  Port Elizabeth ◦ Volume throughput − Sterile vials/amps now online − Contained suite  Objective to realise majority of synergies ◦ FY20

  54. Slide 54: USA opportunity

    USA opportunity  In addition to existing IP ◦ Aspen acquired and developed broad IP/technological capabilities  Increased emphasis/focus on the USA ◦ Base business is performing ◦ Scope for substantial improvement  Leverage existing IP ◦ Key registrations anticipated ◦ Dossiers acquired/developed

  55. Slide 55: Summary and Prospects

    Summary and Prospects  Aspen has had another successful year ◦ 34th consecutive growth report  In spite of negative currency headwinds ◦ Revenue +22% ◦ Normalised HEPS +15% ◦ Cash from operating activities +26%  In addition to achieving the above ◦ We have settled & transitioned complex multibill

  56. Slide 56: Summary and Prospects

    Summary and Prospects  Aspen continues to drive focus ◦ Key therapeutic areas ◦ Intention global/regional leadership ◦ Seamlessly manage complexity ◦ Leverage operational/technical skill base ◦ Deliver on synergies  Global industry is dynamic ◦ Significant M&A activity ◦ Aspen extremely well posit

  57. Slide 57: Summary and Prospects

    Summary and Prospects  Reviewing broad strategic opportunities/partnerships in Pharma ◦ Complement/enhance existing strengths ◦ Clarity/give focus to future strategic direction  Aspen’s strength however is ◦ Not dependant on inorganic activity for growth ◦ Significant organic opportunity − Over R2

  58. Slide 58: END

    END

  59. Slide 59: Disclaimer

    Disclaimer Cautionary regarding forward-looking statements This presentation has been prepared by Aspen Pharmacare Holdings Limited based on information available to it as at the date of the presentation. This presentation may contain prospects, projections, future plans and expectations, strategy a

  60. Slide 60: Appendices

    Appendices Appendix 1: Group statement of financial position Appendix 2: Extract from Group statement of cash flows Appendix 3: Segmental revenue and normalised EBITA Appendix 4: Institutional investors Appendix 5: Corporate activity Appendix 6: Expansion of Aspen footprint in Sub-Saharan Africa App

  61. Slide 61: Group statement of financial position

    Appendix 1 Group statement of financial position As at 30 June R’million FY 2015 FY 2014 ASSETS Non-current assets 55 680 51 334 Property, plant and equipment 7 917 7 151 Intangible assets 40 522 35 699 Goodwill 5 026 6 641 Contingent environmental indemnification asset 677 727 Other non-current ass

  62. Slide 62: Extract from Group statement of cash flows

    Appendix 2 Extract from Group statement of cash flows For the year ended 30 June R’million FY 2015 FY 2014 Change Cash operating profit 9 507 7 911 20% Changes in working capital (1 467) (2 187) Cash generated from operations 8 040 5 724 40% Net finance costs paid (2 007) (709) Tax paid (1 194) (1 1

  63. Slide 63: Segmental revenue and normalised EBITA

    Appendix 3 Segmental revenue and normalised EBITA Gross revenue by region Normalised EBITA* by region 100% 100% 3% 4% 4% 4% 9% 10% 9% 7% 90% 90% 24% 21% 80% 24% 23% 80% 35% 70% 35% 70% 60% 19% 55% 60% 21% 60% 25% 27% 50% 50% 34% 40% 40% 37% 6% 30% 13% 30% 56% 49% 47% 20% 40% 20% 31% 27% 10% 23% 18%

  64. Slide 64: Institutional investors

    Appendix 4 Institutional investors 100% 90% 80% 70% Southern Africa 60% North America 50% Europe 40% Asia Pacific 30% Middle East 20% 10% 0% June 2011 June 2012 June 2013 June 2014 June 2015 64

  65. Slide 65: Corporate activity

    Appendix 5 Corporate activity  Disposal of Fondaparinux molecules in the United States to Mylan ◦ Prompted by lack of knowledge of the US generic sector ◦ USD300 million consideration  Acquisition of 50% of New Zealand New Milk ◦ Supply of infant milk formula for distribution in Australia ◦ Holds

  66. Slide 66: Corporate activity (continued)

    Appendix 5 Corporate activity (continued)  Disposal of generics business and certain branded products to Strides ◦ Aspen Australia divested approximately 130 products for approximately AUD217 million ◦ 2015 revenue of R1.2 billion ◦ Aspen Global divested six branded products for approximately USD79

  67. Slide 67: Expansion of Aspen footprint in Sub-Saharan Africa

    Appendix 6 Expansion of Aspen footprint in Sub-Saharan Africa  Kama Industries Limited ◦ Established and reputable business based in Accra, Ghana ◦ Acquired 65% of business for USD4.5 million ◦ Effective 1 May 2015 ◦ Revenue of R2.3 million for FY2015 ◦ Options to acquire the remaining 35% over tim

  68. Slide 68: Asia Pacific – Japan entity

    Appendix 7 Asia Pacific – Japan entity  Japan ◦ Commenced trading on 1 July 2015 ◦ In the process of finalising a collaboration arrangement with GSK to launch authorised generics − Rapidly expanding sector − Driven by government’s initiative to manage escalating healthcare costs − Registration of a

Aspen Pharmacare Holdings — FY2015 Earnings Presentation on 6ix